Efficacy of boceprevir-based triple therapy in patients with hepatitis C recurrence after liver transplant

Trial Profile

Efficacy of boceprevir-based triple therapy in patients with hepatitis C recurrence after liver transplant

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2013

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2013 New trial record
    • 22 May 2013 6-month results reported at the 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top